427 related articles for article (PubMed ID: 12519616)
21. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease.
Chong J; Karner C; Poole P
Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD009157. PubMed ID: 22972134
[TBL] [Abstract][Full Text] [Related]
22. Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma.
Ni Chroinin M; Greenstone IR; Danish A; Magdolinos H; Masse V; Zhang X; Ducharme FM
Cochrane Database Syst Rev; 2005 Oct; (4):CD005535. PubMed ID: 16235410
[TBL] [Abstract][Full Text] [Related]
23. Long-acting beta(2)-agonists in management of childhood asthma: A critical review of the literature.
Bisgaard H
Pediatr Pulmonol; 2000 Mar; 29(3):221-34. PubMed ID: 10686044
[TBL] [Abstract][Full Text] [Related]
24. Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events.
Cates CJ; Lasserson TJ
Cochrane Database Syst Rev; 2010 Jan; (1):CD007694. PubMed ID: 20091646
[TBL] [Abstract][Full Text] [Related]
25. Inhaled short acting beta2-agonist use in asthma: regular vs as needed treatment.
Walters EH; Walters J
Cochrane Database Syst Rev; 2000; 2003(4):CD001285. PubMed ID: 11034709
[TBL] [Abstract][Full Text] [Related]
26. Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events.
Cates CJ; Lasserson TJ
Sao Paulo Med J; 2010; 128(5):310-1. PubMed ID: 21181075
[TBL] [Abstract][Full Text] [Related]
27. Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events.
Cates CJ; Lasserson TJ
Cochrane Database Syst Rev; 2009 Oct; (4):CD007695. PubMed ID: 19821436
[TBL] [Abstract][Full Text] [Related]
28. A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol.
Lipworth BJ; Aziz I
J Allergy Clin Immunol; 1999 Jan; 103(1 Pt 1):88-92. PubMed ID: 9893190
[TBL] [Abstract][Full Text] [Related]
29. Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children.
Chauhan BF; Chartrand C; Ni Chroinin M; Milan SJ; Ducharme FM
Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD007949. PubMed ID: 26594816
[TBL] [Abstract][Full Text] [Related]
30. Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation.
Appleton S; Poole P; Smith B; Veale A; Bara A
Cochrane Database Syst Rev; 2002; (3):CD001104. PubMed ID: 12137617
[TBL] [Abstract][Full Text] [Related]
31. Airway subsensitivity with long-acting beta 2-agonists. Is there cause for concern?
Lipworth BJ
Drug Saf; 1997 May; 16(5):295-308. PubMed ID: 9187530
[TBL] [Abstract][Full Text] [Related]
32. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma.
D'Alonzo GE; Nathan RA; Henochowicz S; Morris RJ; Ratner P; Rennard SI
JAMA; 1994 May; 271(18):1412-6. PubMed ID: 7909853
[TBL] [Abstract][Full Text] [Related]
33. Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma.
Crossingham I; Turner S; Ramakrishnan S; Fries A; Gowell M; Yasmin F; Richardson R; Webb P; O'Boyle E; Hinks TS
Cochrane Database Syst Rev; 2021 May; 5(5):CD013518. PubMed ID: 33945639
[TBL] [Abstract][Full Text] [Related]
34. Short-acting beta 2 agonists for stable COPD.
Sestini P; Renzoni E; Robinson S; Poole P; Ram FS
Cochrane Database Syst Rev; 2000; (3):CD001495. PubMed ID: 10908502
[TBL] [Abstract][Full Text] [Related]
35. Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children.
Kew KM; Karner C; Mindus SM; Ferrara G
Cochrane Database Syst Rev; 2013 Dec; (12):CD009019. PubMed ID: 24343671
[TBL] [Abstract][Full Text] [Related]
36. Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian Formoterol Study Investigators.
van der Molen T; Postma DS; Turner MO; Jong BM; Malo JL; Chapman K; Grossman R; de Graaff CS; Riemersma RA; Sears MR
Thorax; 1997 Jun; 52(6):535-9. PubMed ID: 9227720
[TBL] [Abstract][Full Text] [Related]
37. Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events.
Cates CJ; Lasserson TJ
Cochrane Database Syst Rev; 2012 Mar; 3(3):CD007695. PubMed ID: 22419326
[TBL] [Abstract][Full Text] [Related]
38. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
Farne HA; Cates CJ
Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945
[TBL] [Abstract][Full Text] [Related]
39. Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children.
Lasserson TJ; Ferrara G; Casali L
Cochrane Database Syst Rev; 2011 Dec; (12):CD004106. PubMed ID: 22161385
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the efficacy of formoterol and salmeterol in patients with reversible obstructive airway disease: a multicenter, randomized, open-label trial.
Condemi JJ
Clin Ther; 2001 Sep; 23(9):1529-41. PubMed ID: 11589265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
